Genetics

More

Agena Bioscience GmbH

Agena Bioscience - MassARRAY Colon Panel

Target:  >200 clinically actionable somatic mutations in four principal oncogenes (KRAS, BRAF NRAS, PIK3CA)

Sample throughput: Up to 10 patient samples and 2 controls per plate

Sample amount:40ng DNA per sample

No of multiplexed PCR reactions: 8

Sensitivity: Detection and analysis of mutation frequencies as low as 5%

MassARRAY Dx Colon Panel is a CE-IVD approved set of clinically validated assays for cost-effective, accurate mutation screening to help you rapidly profile actionable somatic mutations in KRAS, BRAF, NRAS, and PIK3CA genes. The kit includes the required controls (wild-type and negative). The Panel is based upon clinical practice guidelines for diagnosis, treatment and follow-up for metastatic colorectal cancer recommended by ESMO.

Agena Bioscience GmbH

Mendelssohnstraße 15D
22761 Hamburg
Germany

Related products

Clinical chemistry

Agena Bioscience - MassARRAY Dx Nanodispenser RS 1000

Agena Bioscience GmbH

Amplification/Detection

Agena Bioscience - MassARRAY Dx Analyzer 4

Agena Bioscience GmbH

Amplification/Detection

Agena Bioscience - MassARRAY Dx Lung Panel

Agena Bioscience GmbH

Amplification/Detection

Agena Bioscience - MassARRAY Colon Panel

Agena Bioscience GmbH